Financings Roundup
Blend Gets $16M in Series B; Brewing Platinum Nano-Drug
With a new CEO and $16 million in Series B money, combination-drug developer Blend Therapeutics Inc. is putting oomph behind a platinum-based therapy a new chemical entity unto itself to be made with the company's nanoparticle technology.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.